Reviewers winnowed an initial 27 assays to a group of nine that were evaluated using NCI sample sets, ultimately choosing ClearNote's Avantect and Guardant's Shield.

Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast ‘Ned’ Sharpless and ‘Ned’ David form Jupiter Bioventures to test ideas with efficiency ...